Why the study?
Immune checkpoint inhibitors are associated with cardiotoxicities like myocarditis, but data on the implementation and clinical outcomes of cardiac biomarker screening remain limited.
Does routine cTnI surveillance integrated with symptom-based triaging help identify and manage cardiotoxicities in patients receiving immunotherapy?
Population
428 adults undergoing routine serial cTnI monitoring during immunotherapy
Comparison
Symptomatic vs asymptomatic patients with elevated cTnI
Design
Single-center retrospective cohort study
Follow-up
24 months
Authors
Loading...
cTnI surveillance with symptom-based triaging may enable earlier cardiotoxicity management; hypothesis-generating and should not yet change practice.
Does routine cTnI surveillance integrated with symptom-based triaging help identify and manage cardiotoxicities in patients receiving immunotherapy?
Routine cTnI surveillance with symptom-based triaging in patients on immunotherapy identifies asymptomatic cardiotoxicity allowing for continued therapy, while highlighting that symptomatic cTnI elevation carries a significantly higher risk of MACE and mortality.
Cheng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: